Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Umbralisib · Ukoniq, TGR-1202

Small molecule · Inhibitor of phosphoinositide 3-kinase delta (PIK3CD) and casein kinase 1 epsilon (CSNK1E) · developed by Tg Theraps

Approved FDA, Feb 2021
6 Registered trials

What is Umbralisib?

Umbralisib is an orally available kinase inhibitor that targets the delta isoform of PI3K and casein kinase 1 epsilon, suppressing PI3K/AKT signaling and reducing proliferation and migration of B-cell lymphoma cells.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Ukoniq, TGR-1202, UKONIQ, RP-5264
Drug type
Small molecule
Targets
phosphoinositide 3-kinase delta (PIK3CD), casein kinase 1 epsilon (CSNK1E), ABL1 (mutated form) (ABL1) (secondary target)
Mechanism
Inhibitor of phosphoinositide 3-kinase delta (PIK3CD) and casein kinase 1 epsilon (CSNK1E)
Pathways
PI3K/AKT signaling, CXCL12-mediated cell adhesion, CCL19-mediated cell migration
Therapy area
Oncology
Developer
Tg Theraps
In trials of
TGTX
FDA status
Approved as Ukoniq (February 5, 2021), NDA213176 · FDA label
UNII
38073MQB2A

✅ FDA-approved uses

From the indications section of the FDA label (version of Dec 15, 2022). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03801525 Phase 2/3 Chronic Lymphocytic Leukemia Terminated TGTX
NCT02612311 Phase 3 Chronic Lymphocytic Leukemia Terminated TGTX
NCT03207256 Phase 2 Chronic Lymphocytic Leukemia Terminated TGTX
NCT02164006 Phase 1 Hodgkin's Lymphoma Completed TGTX
NCT02100852 Phase 1 Chronic Lymphocytic Leukemia Completed TGTX
NCT02006485 Phase 1 Chronic Lymphocytic Leukemia Completed TGTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Lymphocytic LeukemiaNon Hodgkin LymphomaNon-Hodgkin's LymphomaSmall Lymphocytic Lymphoma

Other drugs acting on PIK3CD / CSNK1E

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.